Pharmacological treatment of Alzheimer's disease;Tratamento farmacológico da doença de Alzheimer

Revista de Psiquiatria Clinica

Volumn 32, Issue 3, 2005, Pages 137-148

  Forlenza, Orestes V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer's disease; Amyloid; Dementia; Pharmacology; Treatment

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID; ANTIOXIDANT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; NERVE GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; DEMENTIA; DRUG METABOLISM; ESTROGEN THERAPY; HUMAN; IMMUNOTHERAPY; PATHOGENESIS; REVIEW;

EID: 23044482655     PISSN: 01016083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. AISEN, P.S.; SCHAFER, K.A.; GRUNDMAN, M. ET AL. - Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-26.
2. BIRKS, J.; FLICKER, L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2003;1:CD000442.
3. BIRKS, J.; GRIMLEY, E.V.; VAN DONGEN, M. - Ginkgo biloba for cognitive impairment and dementia (Cochrane Review). In: Cochrane Library. Cochrane Database Syst Rev 4: CD003120, 2002.
4. CHECK, E. - Nerve inflammation halts trial for Alzheimer's drug. Nature 2002;415(6871):462.
5. CIRRITO, J.R.; HOLTZMAN, D.M. - Amyloid-b and Alzheimer disease therapeutics: the devil may be in the details. J Clin Invest 2003;112:3.
6. COURTNEY, C.; FARRELL, D.; GRAY R. et al. - Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363(9427):2105-15.
7. DE FELICE, F.G.; FERREIRA, S.T. - Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell Mol Neurobiol 2002;22(56):545-63.
8. EVANS, R.M.; HUI, S.; PERKINS, A. et al. - Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 2004;62(10):1869-71.
9. FINEFROCK, A.E.; BUSH, A.I.; Doraiswamy, P.M. - Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc 2003;51(8):1143-8.
10. FOX, N.C.; BLACK, R.S.; GILMAN, S. et al. - Effects of A-Beta Immunotherapy (AN1792) on MRI Measures of Brain, Ventricle and Hippocampal Volumes in Alzheimer's Disease. Neurobiol Aging 2004;25(S2):84.
11. GEERTS, H. - NC-531 (Neurochem). Curr Opin Investig Drugs 2004;5(1):95-100.
12. GILMAN, S.; KOLLER, M.; BLACK, R.S. et al. - Neuropsychological, CSF, and neuropathological effects of A-beta immunotherapy (AN1792) of Alzheimer's disease in an interrupted trial. Neurobiol Aging 2004;25(S2):84.
13. GREEN, P.S.; GRIDLEY KE.; SIMPKINS JW. - Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett 1996;218(3):165-8.
14. HENDERSON, V.W.; PAGANINI-HILL, A.; MILLER, B.L. et al. - Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54(2):295-301.
15. HUANG, T.H.; YANG, D.S.; FRASER, P.E.; Chakrabartty, A. - Alternate aggregation pathways of the Alzheimer beta-amyloid peptide. An in vitro model of preamyloid. J Biol Chem 2000;275(46):36436-40.
16. IN'T VELD, B.A.; LAUNER, L.J.; HOES, A.W. et al. - NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging 1998;19(6):607-11.
17. INT' VELD, B.A.; RUITENBERG, A.; HOFMAN, A.; LAUNER, L.J.; VAN DUIJN, C.M.; STIJNEN, T.; BRETELER M.M.; STRICKER, B.H. - Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-21.
18. JANN, M.V. - Pharmacology and clinical efficacy of cholinesterase inhibitors - Am J Health Syst Pharm 1998;55(Suppl 2):S22-5.
19. JANUS, C.; PEARSON, J.; MCLAURIN, J. et al. - A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408(6815):979-82.
20. JARVIS, B.; FIGGITT, D.P. - Memantine. Drugs Aging 2003;20(6):465-76.
21. Kennedy, D.O.; Scholey, A.B.; Wesnes, K.A. - The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology (Berl) 2000;151(4):416-23.
22. LANCTÔT, K.L.; HERRMANN, N.; YAU, K.K.; et al. - Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169(6):557-64.
23. LE BARS, P.L.; KATZ, M.M.; BERMAN, N. et al. - A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997;278(16):1327-32.
24. LE BARS, P.L.; VELASCO, F.M.; FERGUSON, J.M. et al. - Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology 200245(1):19-26.
25. LEBERT, F. - Treatment of frontotemporal dementia. Psychol Neuropsychiatr Vieil 2004;2(1):35-42.
26. LI, G.; HIGDON, R.; KUKULL, W.A. et al. - Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004;63(9):1624-8.
27. LI, S.; MALLORY, M.; ALFORD, M. et al. - Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 1997;56(8):901-11.
28. LIM, G.P.; YANG, F.; CHU, T. et al. - Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 2001;22(6):983-91.
29. LOVESTONE. S.; GRAHAM. N.; HOWARD. R. - Guidelines on drug treatments for Alzheimer's disease. Lancet 1997;350:752-68.
30. LUO, Y.; SMITH. J;V.; PARAMASIVAM V.; et al. - Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002;99(19):12197-202.
31. LUO, Y. - Ginkgo biloba neuroprotection: therapeutic implications in Alzheimer's disease. J Alzheimer's Dis 2001;3(4):401-7.
32. MESULAM, M.M.; GEULA, C. - Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36(5):722-7.
33. MISZTAL, M.; FRANKIEWICZ, T.; PARSONS, C.G. et al. - Learning deficits induced by chronic intraventricular infusion of quinolinic acid-protection by MK-801 and memantine. Eur J Pharmacol 1996;296(1):1-8.
34. MIX, J.A.; CREWS, W.D JR. - A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 2002;17(6):267-77.
35. MONSONEGO, A.; ZOTA, V.; KARNI, A. et al. - Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003;112(3):415-22.
36. MORGAN, D.; DIAMOND, D.M.; GOTTSCHALL, P.E.; et al. - A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408(6815):982-5.
37. MULNARD, R.A.; COTMAN, C.W.; KAWAS, C. et al. - Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000;283(8):1007-15.
38. NICOLL, J.A.; WILKINSON, D.; HOLMES C. et al. - Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9(4):448-52.
39. NORDBERG, A. - New targets for Alzheimer therapy. In: Iqbal K, Winblad B. (ed.) Alzheimer's Disease and Related Disorders: Research Advances. Bucharest, Romania: Ana Asian International Academy of Aging 2003, pp.499-512.
40. ORGOGOZO, J.M.; GILMAN, S.; DARTIGUES, J.F. et al. - Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61(1):46-54.
41. PANTEV, M.; RITTER, R.; GÖRTELMEYER, R. - Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under Memantine treatment. Zeitschrift für Gerontopsychologie und -psychiatrie 1993;6:103-17.
42. PARSONS, C.G.; GRUNER, R.; ROZENTAL, J. et al. - Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 1993;32(12):1337-50.
43. REISBERG, B.; DOODY, R.; STOFFLER, A. et al. - Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348(14):1333-41.
44. RIGNEY, U.; KIMBER, S.; HINDMARCH, I. - The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. Phytother Res 1999;13(5):408-15.
45. RITCHIE, C.W.; BUSH, A.I.; MACKINNON, A. et al. - Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60(12):1685-91.
46. ROCKWOOD, K. - Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75(5) 677-85.
47. ROGAWSKI, M.A.; WENK, G.L. - The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 2003;9(3):275-308.
48. SANO, M.; ERNESTO, C.; THOMAS, R.G. - A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22.
49. SASTRE, J.; PALLARDO, F.V.; VINA, J. - Mitochondrial oxidative stress plays a key role in aging and apoptosis. IUBMB Life 2000;49(5):427-35.
50. SCHENK, D.; BARBOUR, R.; DUNN, W. et al. - Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP. Nature 1999;400(6740):173-7.
51. SHUMAKER, S.A.; LEGAULT, C.; KULLER, L. et al. - Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291(24):2947-58.
52. SHUMAKER SA.; LEGAULT C.; RAPP SR.; et al. - Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289(20):2651-62.
53. SIEMERS, E.; DEAN, R.A.; SATTERWHITE J.; et al. - Safety, tolerability, and changes in plasma and cerebrospinal fluid amyloid beta concentrations after administration of a functional gamma-secretase inhibitor in healthy volunteers. Neurobiol Aging 2004;25(S2):569.
54. TABET, N.; FELDMAND, H. - Ibuprofen for Alzheimer's disease. Cochrane Database Syst Rev 2003;2:CD004031.
55. TARIOT, P.N.; FARLOW, M.R.; GROSSBERG, G.T. et al. - Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291(3):317-24.
56. WENK, G.L.; QUACK, G.; MOEBIUS, H.J. et al. - No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci 2000;66(12):1079-83.
57. WHITE, A.R.; HAWKE, S.H. - Immunotherapy as a therapeutic treatment for neurodegenerative disorders. J Neurochem 2003;87:801-8.
58. WINBLAD, B.; PORITIS, N. - Memantine in severe dementia: results of the 9M-Best Study Benefit and efficacy in severely demented patients during treatment with memantine. Int J Geriatr Psychiatry 1999;14(2):135-46.
59. ZANDI, P.P.; SPARKS, D.L; Khachaturian, A.S. et al. - Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005;62(2):217-24.
60. ZHOU, L.J.; ZHU, X.Z. - Reactive oxygen species-induced apoptosis in PC12 cells and protective effect of bilobalide. J Pharmacol Exp Ther, 2000;293(3):982-8.